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Increased smooth muscle mass due to hyperplasia and hypertrophy of airway smooth muscle (ASM) cells
is a common feature in asthma. Angiotensin II (Ang II), a potent vasoconstrictor and mitogen for a wide
variety of cells, has recently been implicated in bronchoconstriction in asthmatics. However, a possible
mitogenic role as well as underlying molecular mechanisms of this octapeptide in human ASM cells are
not yet known. We studied the effects of Ang II on ASM cell proliferation and growth and on the expres-
sion of three transcription factors, egr-1, c-fos, and c-jun, as well as a cytokine, transforming growth fac-
tor-
 
b
 
1
 
 (TGF-
 
b
 
1
 
). Human ASM cells were isolated by enzymatic digestion of bronchial smooth muscle ob-
tained from lung resection tissue. Confluent cells were growth-arrested and subsequently incubated with
Ang II (100 nM) for different time periods and processed for the measurement of cell growth and gene ex-
pression. Ang II significantly induced DNA and protein synthesis in human ASM cells at 8 h, resulting in
a net increase in the accumulation of protein over DNA (i.e., cellular hypertrophy) at 16 h of incubation.
Cell counts and MTT-reduction assay, however, showed no increase in cell number as a result of Ang II
stimulation. Ang II stimulated the expression of egr-1 and c-fos as early as 15 min, reaching maximum
levels at 45 min, whereas the expression of c-jun peaked at 2 h of Ang II exposure. Furthermore, steady-
state mRNA levels of TGF-
 
b
 
1
 
 were upregulated by Ang II after 4 h and reached peak levels at 16 h of in-
cubation. Secretion of biologically active TGF-
 
b
 
1
 
 from human ASM cells was significantly (
 
P
 
 
 
<
 
 0.02) en-
hanced by Ang II incubation after 8 h, which remained elevated until 24 h. Our results suggest that the Ang
II-induced transient early expression of transcription factors may regulate autocrine genes like TGF-
 
b
 
1
 
, of
which the subsequent late upregulation could contribute to cellular hypertrophy during, for example, air-
way remodeling in asthma. 
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Airway remodeling with inflammatory cell infiltration,
epithelial shedding, basement membrane thickening, and
increased mass of airway smooth muscle (ASM) is an im-
portant determinant of bronchial obstruction and hyperre-
sponsiveness in asthma (1–4). Studies using detailed com-
puter models of human airways indicate that increased
ASM mass is by far the most important abnormality re-
sponsible for excessive airway narrowing and compliance
of the airway wall in asthma (1, 5). In analogy to vascular
smooth muscle accumulation in hypertension and athero-
sclerosis, ASM growth in asthma is a complex phenome-
non of which the underlying mechanisms are difficult to
investigate 
 
in vivo
 
. The increased amount of ASM in asth-
matics is an indication of abnormal cell proliferation and
growth. Both hyperplastic (i.e., increase in cell number)
and hypertrophic (i.e., increase in cell size) changes con-
tribute to the increased smooth muscle content of the air-
way wall (1, 2, 6, 7), but little is known regarding the mo-
lecular mechanisms and factors that regulate ASM cell
proliferation and growth in asthma.
Recently, a number of growth factors and cytokines de-
rived from inflammatory cells have been implicated in
ASM cell division and growth (8–12). The potent circulat-
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ing hormone of the renin–angiotensin system, angiotensin
II (Ang II) has been implicated in bronchoconstriction in
mild asthmatics (13). Plasma levels of Ang II have been
shown to be elevated in patients with acute severe asthma
(14). At plasma levels similar to those observed in acute
asthma, Ang II was found to enhance methacholine-
evoked bronchoconstriction, both in human bronchi 
 
in
vitro
 
 and in mild asthmatics 
 
in vivo
 
, thus suggesting a
novel role for Ang II as a putative mediator in asthma
(13). Although Ang II has been shown to stimulate prolif-
eration and
 
/
 
or hypertrophy in a wide variety of cells, such
as cardiac myocytes, cardiac fibroblasts, and vascular smooth
muscle cells (15–17), it remains to be established whether
this octapeptide stimulates proliferation and growth of ASM
cells.
It is known that growth and differentiation factors stim-
ulate signal transduction pathways in the cell leading to
the expression of nuclear proto-oncogenes that include the
Fos, Jun, and Egr families (18). Fos and Jun proteins con-
stitute the heterodimer AP-1 (19). The AP-1 and egr-1
transcription factors can regulate a number of target genes
during growth factor stimulation and thereby influence
cellular growth and differentiation (16, 20, 21). Ang II has
been shown to induce a rapid increase in the expression of
c-fos and c-jun (members of the leucine zipper family) and
egr-1 (a member of the zinc finger family) in vascular
smooth muscle cells as well as in cardiac fibroblasts prior
to hypertrophy and
 
/
 
or hyperplasia (16, 20, 22). Further-
more, an important cytokine, transforming growth factor-
 
b
 
1
 
 (TGF-
 
b
 
1
 
), has synergistically been associated with Ang
II. TGF-
 
b
 
1
 
 is synthesized as a biologically inactive propep-
tide which must be cleaved to form the active peptide, by
proteases such as plasmin (23), before it can exert its func-
tion in tissue repair after injury or act as a regulatory pep-
tide in remodeling processes in various tissues, including
the heart and the lung (16, 24, 25). Also, TGF-
 
b
 
1
 
 stimu-
lates the synthesis of extracellular matrix components such
as collagens and fibronectin in response to Ang II in vas-
cular smooth muscle cells (17, 25, 26).
To elucidate the potential role of Ang II in ASM growth
in asthma, we investigated hyperplasia and hypertrophy in
cultured human ASM cells and examined the expression
pattern of three proto-oncogenes, namely, egr-1, c-fos, and
c-jun. Additionally, we studied the expression of the extra-
cellular matrix regulator TGF-
 
b
 
1
 
 both at mRNA and pro-
tein levels in human ASM cells treated with Ang II.
 
Materials and Methods
 
Materials
 
Bovine serum albumin (BSA), collagenase, elastase, apo-
transferrin, ascorbate, insulin, non-enzymatic cell dissocia-
tion solution, mouse monoclonal anti-
 
a
 
 smooth muscle
actin and anti-smooth muscle myosin, antimouse IgG fluo-
rescein isothiocyanate (FITC) conjugate, 4
 
9
 
,6-diamidino-
2-phenylindole-2HCl, calf thymus DNA, herring sperm
DNA, and trypan blue were purchased from Sigma-Ald-
rich BV (Zwijndrecht, The Netherlands). Hanks’ balanced
salt solution (HBSS), Dulbecco’s modified Eagle’s medium
(DMEM), sodium pyruvate, MEM nonessential amino
acids, gentamicin, penicillin:streptomycin, Fungizone
 
/
 
am-
photericin B, and trypsin-ethylenediamenetetraacetic acid
(EDTA) were purchased from Life Technologies BV
(Breda, The Netherlands). Fetal bovine serum (FBS) was
purchased from Bio-Whitaker BV (Verviers, Belgium).
[
 
Methyl
 
-
 
3
 
H]thymidine, [
 
methyl
 
-
 
3
 
H]leucine, (
 
a
 
-P
 
32
 
)-dCTP,
hybond-N, and redi-prime labeling kit were obtained from
Amersham Nederland BV (
 
9
 
s-Hertogenbosch, The Neth-
erlands). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tet-
razolium bromide (MTT)-reduction assay kit was obtained
from Boehringer Mannheim GmbH (Mannheim, Germany).
The TGF-
 
b
 
1
 
 E
 
max
 
 ImmunoAssay System was procured from
Promega Corp. BNL (Leiden, The Netherlands). Anti-
cytokeratin and anti-
 
a
 
-CD31 antibodies were obtained
from Dako A
 
/
 
S (Glostrup, Denmark). The cDNA probe
for human-specific glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) was obtained from American Type Cul-
ture Collection (Rockville, MD). Tissue culture plasticware
was obtained from Life Technologies BV. All other chemi-
cals were of molecular biology and
 
/
 
or tissue culture grade
and were procured from local suppliers.
 
Cell Culture
 
Human airway smooth muscle cells were isolated and cul-
tured according to the methods described previously (10,
27). Briefly, bronchial smooth muscle was dissected from
the lobar or main bronchus from lung resection specimens
obtained from patients undergoing surgery for lung can-
cer. After removal of the epithelium, pieces of macroscop-
ically normal smooth muscle were dissected free of adher-
ent connective and parenchymal tissue under aseptic
conditions. Smooth muscle pieces were incubated in HBSS
containing 10 mg
 
/
 
ml of BSA (fraction V), collagenase
(type XI, 1 mg
 
/
 
ml), and elastase (type IV, 3.3 U
 
/
 
ml) at
37
 
8
 
C in a humidified ASSAB model T154 CO
 
2
 
 incubator
(Clean Air Techniek BV, Woerden, The Netherlands).
After enzymatic digestion, the tissue was centrifuged and
the resultant pellet was washed in DMEM containing 10%
(vol
 
/
 
vol) FBS supplemented with sodium pyruvate (1 mM),
nonessential amino acid mixture (1:100), gentamicin (45
 
m
 
g
 
/
 
ml), penicillin (100 U
 
/
 
ml), streptomycin (100 
 
m
 
g
 
/
 
ml),
and amphotericin B (1.5 
 
m
 
g
 
/
 
ml), and subsequently seeded
at 2 
 
3
 
 10
 
5
 
 cells per 35-mm dish. Fresh medium was re-
placed every 72 h. After 10–14 d in culture, ASM cells
grew to confluence and were then removed from the plas-
tic base of each dish using non-enzymatic cell dissociation
buffer and subcultured into tissue culture flasks. At con-
fluency, cells were further passaged by means of trypsiniza-
tion. Confluent cells in the fifth passage were used for ex-
periments.
 
Immunocytochemical Characterization of ASM Cells
 
Monoclonal antibodies against 
 
a
 
-smooth muscle actin and
smooth muscle cell specific myosin (SM-1 and SM-2) were
used as markers to characterize human ASM cells in cul-
ture (28). Cells were allowed to attach to multiwell slides
for 24 h in FBS-containing medium and were subsequently
growth-arrested by incubating for 60–72 h in FBS-free
DMEM supplemented with apo-transferrin (5 
 
m
 
g
 
/
 
ml),
ascorbate (100 
 
m
 
M), and insulin (1 
 
m
 
M) prior to fixation
and staining. Following two washes in ice-cold phosphate-
buffered saline (PBS; 140 mM NaCl, 2.6 mM KCl, 1.4 mM
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KH
 
2
 
PO
 
4
 
, 8.1 mM Na
 
2
 
HPO
 
4
 
 · 2 H
 
2
 
O, pH 7.4), the cells were
fixed in ice-cold methanol and permeabilized in PBS con-
taining 0.1% Tween-20. Nonspecific binding was blocked
by incubating the cells in 1% BSA in PBS, and the cells
were then washed and subsequently incubated with anti-
 
a
 
smooth muscle actin or anti-smooth muscle myosin antibod-
ies. After incubation, the cells were washed twice in PBS
and further incubated with affinity purified FITC-conju-
gated antimouse antibody. Unbound antibody was washed
away using distilled water and the sections were dehydrated
and mounted in glycerol. Specimens were visualized under
a fluorescence microscope (Carl Zeiss BV, Weesp, The Neth-
erlands) and photographed. Human ASM cells stained
positive for anti-
 
a
 
 smooth muscle actin and anti-smooth
muscle myosin. Additionally, the cultures were stained for
endothelial and epithelial cell contamination using anti-
CD31 and anti-cytokeratin antibodies, respectively. The
staining showed that human ASM cell cultures were essen-
tially free (
 
.
 
 95%) of other contaminating cell types. Un-
der the light microscope, the human ASM cells appeared
elongated and spindle-shaped with central oval nuclei con-
taining prominent nucleoli. Confluent human ASM cells in
culture showed a specific pattern, aligned in parallel so
that the broad nuclear region of one cell lies adjacent to
the thin cytoplasmic area of another, giving rise to a typi-
cal “hill and valley” appearance as described earlier by
Twort and van Breeman (27).
 
RNA Isolation and Northern Blot Analysis
 
Total RNA was extracted from the ASM cells by the
guanidinium thiocynate–phenol–chloroform method de-
scribed previously (16). The RNA concentration was mea-
sured by spectrophotometry. For Northern hybridization,
samples of total RNA were denatured at 65
 
8
 
C and size-
fractionated on a 1% agarose gel containing 2.2 M formal-
dehyde. Ethidium bromide-stained gels were photographed
and RNA was transferred to hybond-N membrane by al-
kaline downward capillary transfer (29). The filters were
air-dried and ultraviolet crosslinked in a gene linker (Bio-
Rad Labs BV, Veenendaal, The Netherlands). Blots were
hybridized at 42
 
8
 
C in a buffer containing 50% deionized
formamide, 1.0 M sodium chloride, 1% sodium dodecyl
sulfate (SDS), 0.2% polyvinyl pyrrolidone, 0.2% ficoll,
0.2% BSA, 50 mM Tris-HCl (pH 7.5), 0.1% sodium pyro-
phosphate, 2% dextran sulphate, and denatured herring
sperm DNA (2 mg
 
/
 
ml). The cDNA probes used for hybrid-
ization were: mouse c-fos (2.1-kb fragment), mouse c-jun
(2.6-kb fragment), mouse egr-1 (300-bp fragment of zinc fin-
ger region), and human TGF-
 
b
 
1
 
 (1,050-bp fragment). These
inserts were labeled with the redi-prime labeling system to
a specific activity of approximately 10
 
9
 
 cpm
 
/m
 
g DNA. Fil-
ters were washed under stringent conditions, wrapped in
household plastic film, and exposed to Kodak X-OMAT
AR films (Eastman Kodak, Rochester, NY) at 
 
2
 
80
 
8
 
C for 1–
3 d. A GAPDH cDNA probe was used to rehybridize mem-
branes for reference purposes. Hybridization signals were
quantified by scanning laser densitometry using the Ultros-
can XL enhanced laser densitometer (LKB, Bromma, Swe-
den). Densitometric values for each gene were normalized
with respective GAPDH mRNA values and expressed as
relative optical density (OD) in Ang II-stimulated cells
versus control. An optimal concentration of Ang II (100
nM) for the early response of human ASM cells was deter-
mined by incubating growth-arrested cells for 1 h in 10
 
2
 
5
 
,
10
 
2
 
6
 
, 10
 
2
 
7
 
, and 10
 
2
 
8
 
 M [Sar
 
1
 
]-Ang II, and subsequently ex-
amining the expression pattern of the proto-oncogene egr-1. 
 
[
 
3
 
H]Thymidine and [
 
3
 
H]Leucine Incorporation Assays
 
Effects of Ang II on DNA and protein biosynthesis were
assessed by incorporation of [
 
methyl
 
-
 
3
 
H]thymidine and
[
 
methyl
 
-
 
3
 
H]leucine, respectively. An optimum concentra-
tion of Ang II (100 nM) was determined by incubating
growth-arrested ASM cells for 24 h in 10
 
2
 
6
 
, 10
 
2
 
7
 
, 10
 
2
 
8
 
, and
10
 
2
 
9
 
 M [Sar
 
1
 
]-Ang II, and subsequently examining [
 
3
 
H]thy-
midine and [
 
3
 
H]leucine incorporation. Confluent cells were
washed in PBS, detached by trypsinization, and trans-
ferred into 24-well plates at a seeding density of 2 
 
3
 
 10
 
4
 
cells
 
/
 
well. After 5 d in culture the cells were growth-arrested
as described above. Cells were incubated with [
 
methyl
 
-
 
3
 
H]thymidine or [
 
methyl
 
-
 
3
 
H]leucine (1 
 
m
 
Ci
 
/
 
well) in either
fresh FBS-free DMEM (control), FBS-containing DMEM
(
 
1
 
 serum), or DMEM containing 100 nM [Sar
 
1
 
]-Ang II for
4, 8, 16, 24, or 48 h. After stimulation, the cells were
washed in PBS, fixed with ice-cold methanol, and exposed
to ice-cold trichloroacetic acid (5% wt
 
/
 
vol). The acid-insol-
uble fraction was lysed in 0.3 M NaOH and the incorpo-
rated radioactivity was determined in a Packard 1500 Tri-
carb liquid scintillation analyzer (Packard-Becker BV, Delft,
The Netherlands) (9).
 
Assessment of Cellular Hypertrophy and Hyperplasia
 
Protein
 
/
 
DNA ratio. 
 
ASM cell hypertrophy in relation to
Ang II was assessed by calculating the ratio of total pro-
tein to DNA content. Cells were plated at a seeding den-
sity of 2 
 
3
 
 104 cells/well in 24-well plates. After 5 d the
cells were growth-arrested as described above, and then
incubated in either fresh FBS-free DMEM (control), FBS-
containing DMEM (1 serum), or DMEM containing 100
nM [Sar1]-Ang II for 4, 8, 16, 24, or 48 h. After stimulation,
the cells were washed in ice-cold PBS and lysed in 0.3 M
NaOH. The total DNA content was determined fluorimet-
rically using the method described by Kapuscinski and
Skoczylas (30). The total protein content was estimated
colorimetrically using the method described by Bradford
(31). Serial concentrations of calf thymus DNA and BSA
were used for the calibration curves.
MTT assay. In order to assess cellular hyperplasia in
response to Ang II, MTT assays were performed. Cells in
the fifth–sixth passage were transferred to 24-well plates at
a seeding density of 2 3 104 cells/well. After 24 h, the cells
were growth-arrested as described above and subsequently
incubated in either fresh FBS-free DMEM or DMEM
containing 100 nM [Sar1]-Ang II for 4, 8, 16, 24, or 48 h.
Proliferation was assessed using the MTT dye technique,
which relies on the specific metabolic reduction of the tet-
razolium salt MTT by living cells as described earlier (32).
Following incubations, the cells were washed twice in PBS,
200 ml of MTT in DMEM (final concentration 0.5 mg/ml)
was added to each well, and the cells were incubated for
5 h at 378C. After incubation, the blue formazan product
was solubilized by the addition of 200 ml of solubilization
solution (10% SDS in 0.01 M HCl) to each well and incu-
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Figure 1. Northern blot analysis of egr-1, c-fos, and c-jun ex-
pression in human ASM cells treated with Ang II. Total RNA
from control (untreated) and Ang II-treated human ASM
cells at various time points were subjected to Northern hy-
bridization with radiolabeled cDNA probes as described in
MATERIALS AND METHODS. Representative Northern blots
for (A) egr-1 (3.5-kb mRNA band), (B) c-fos (2.2-kb mRNA
band), and (C) c-jun (2.3-kb mRNA band) are shown. ASM
cells were incubated with Ang II (100 nM) in serum-free me-
dium for the times indicated at the top of each panel. Rehy-
bridization of each filter with a GAPDH cDNA probe (lower
part of panel, 1.4-kb mRNA band) was performed for refer-
ence purposes. (D) Line diagram showing quantification of
mRNA expression pattern for different transcription factors
(TF). Scanning densitometric values for each proto-oncogene
were normalized with respective GAPDH mRNA values and
expressed as relative optical density (OD). Results depict the
values from the representative blots. Each experiment was re-
peated at least three times using human ASM cells originating
from different individuals, and each experiment showed a sim-
ilar pattern.
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bating for a further 16 h at 378C. An aliquot of 200 ml from
each duplicate well was then transferred to a 96-well mi-
crotiter plate, and the OD was determined by automated
dual wavelength spectrophotometry (Bio-Rad Labs) at a
test wavelength of 595 nm and a reference of 690 nm. The
change in optical density (DOD), which correlates directly
with change in cell numbers, was plotted against time as
described previously by Hirst and colleagues (10).
Hemocytometry. Cells were seeded into 24-well plates
and treated as described above. Following stimulation, the
medium was removed and the cell monolayers were resus-
pended in 100 ml trypsin-EDTA at room temperature for
10 min. An equal volume of trypan blue was added to the
cell suspension before counting in a Bürker hemocytome-
ter (Marienfeld GmbH, Marienfeld, Germany). At least
120 cells were counted from each well to minimize count-
ing error.
Detection of TGF-b1 Protein in Conditioned Media
Confluent cells in the fifth passage were growth-arrested
as described above, and then incubated in either fresh
FBS-free DMEM (control), FBS-containing DMEM (1 se-
rum), or DMEM containing 100 nM [Sar1]-Ang II for 4, 8,
16, or 24 h. Media were removed and stored at 2208C until
assay. Biologically active TGF-b1 protein was quantified
by enzyme-linked immunosorbent assay (ELISA) using a
TGF-b1 Emax ImmunoAssay System (Promega Corp. BNL,
Leiden, The Netherlands) following the suppliers’ instruc-
tions.
Statistical Analysis
Data are given as means 6 SEM. Statistical analysis was
performed by using the Student’s t test. Significance was
accepted at P < 0.05.
Results
Expression of Transcription Factors in
Relation to Ang II
Representative Northern blots showing the expression
pattern of three proto-oncogenes, following Ang II stimu-
lation of human ASM cells, are shown in Figures 1A–1C.
Ang II induced the expression of mRNAs encoding egr-1
(panel A) and c-fos (panel B) as early as 15 min, while
c-jun expression was increased after 45 min of Ang II stim-
ulation (panel C). Figure 1D shows the quantitative analy-
sis, by scanning laser densitometry, of the Northern blots
for each proto-oncogene. Densitometric analysis revealed
that the induction of c-fos and egr-1 was transient and
reached a maximum at 45 min followed by an abrupt de-
cline; whereas the expression of c-jun was also transient
but reached a maximum at 120 min and gradually returned
to basal levels after 4 h. The relative OD values for the lev-
els of mRNA encoding egr-1, c-fos, and c-jun increased
Figure 1. Continued.
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Figure 2. Ang II-induced DNA (A) and protein (B) biosynthesis in human ASM cells. [3H]Thymidine and [3H]leucine incorporation
were measured in confluent, growth-arrested ASM cells that were stimulated with 100 nM Ang II and compared with untreated cells
(C1 5 4 h; C2 5 48 h) or cells treated with medium containing 10% FBS (1S). Values are calculated from three independent experi-
ments of four determinations each and expressed as specific activity (dpm/ng DNA or dpm/mg protein). *P < 0.05 compared with C1;
#P < 0.05 compared with C2.
Figure 3. Proliferative response of human ASM cells exposed to Ang II. Proliferation was assessed by hemocytometry (A) and by using
the MTT dye technique as described in MATERIALS AND METHODS (B). Values are represented as means 6 SEM of four measure-
ments from three separate experiments. *P < 0.05 compared with control; $P < 0.05 compared with Ang II-treated cells.
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from 0 to their maximum values of 1.97, 2.66, and 0.67, re-
spectively, after Ang II stimulation of human ASM cells.
Effects of Ang II on ASM Proliferation and Growth
The initial aim of this study was to determine whether Ang
II induces an increase in DNA and protein synthesis in
ASM cells made quiescent in defined serum-free medium.
Biosynthesis of DNA and protein from their respective la-
beled precursors (thymidine and leucine) was calculated
as specific activity and represented as dpm/ng DNA (Fig-
ure 2A) or dpm/mg protein (Figure 2B). Data show that
the biosynthesis of both DNA and protein was minimal
until 8 h of Ang II incubation. However, a significant in-
crease was observed in both DNA and protein biosynthe-
sis at 16 h of Ang II stimulation and these levels remained
elevated until 48 h as compared with controls.
In order to assess whether the DNA biosynthesis in hu-
man ASM cells, treated with Ang II, was accompanied
with an increase in cell number, we performed hemocy-
tometry and MTT assays. Data on hemocytometry showed
that Ang II incubation did not significantly increase the
cell number with time as compared with respective con-
trols. However, serum already induced a significant (P <
0.05) increase in cell numbers at 16 h as compared with
controls, and at 48 h cell numbers were considerably
higher (P < 0.001) as compared with respective control
and Ang II-treated cells (Figure 3A). MTT-reduction as-
say data showed no significant change in OD values at 4, 8,
16, 24, or 48 h of Ang II incubation as compared with re-
spective controls, indicating that Ang II did not cause
ASM cell proliferation (Figure 3B).
In a separate set of experiments, the total DNA and
protein contents of the ASM cells were determined in re-
lation to Ang II stimulation with time. Figure 4 shows the
effect of Ang II on the protein/DNA ratio in human ASM
cells. In order to assess Ang II-induced hypertrophy in hu-
man ASM cells, we calculated the protein-to-DNA ratio at
different time points. After 16 h of Ang II incubation, the
protein/DNA ratio of the ASM cells increased signifi-
cantly (P < 0.001) compared with controls, indicating that
the cells were synthesizing more protein than DNA, sug-
gesting cellular hypertrophy. 
Effects of Ang II on TGF-b1 Expression
To evaluate the effects of Ang II on TGF-b1 expression,
we analyzed total cellular RNA from serum-fed ASM cells
and cells stimulated with 100 nM Ang II for various time
intervals and compared the expression pattern with re-
Figure 4. Ang II-induced cellular hypertrophy in human ASM cells. Total DNA and protein contents of ASM cells in the presence and
absence of Ang II (100 nM) were measured. DNA and protein values were calculated from three independent experiments of four de-
terminations each, and the protein/DNA ratio was calculated. Values are expressed as means 6 SEM. C1 5 control (untreated) cells at
4 h; C2 5 control cells at 48 h; 1S 5 cells incubated with medium containing 10% FBS. *P < 0.05 compared with C1; #P < 0.05 com-
pared with C2.
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Figure 5. TGF-b1 mRNA expression in human ASM cells in rela-
tion to Ang II. (A) A representative Northern blot showing the
major 2.5-kb mRNA band encoding TGF-b1. RNA from control
and Ang II-treated human ASM cells was hybridized with a radi-
olabeled human TGF-b1 probe as described in MATERIALS AND
METHODS. Human ASM cells were incubated with Ang II (100
nM) in serum-free medium for the times indicated at the top of
the panel. Filters were reprobed with a radiolabeled GAPDH
cDNA for reference purposes (lower part of panel A). (B) Bar
graph showing quantitative analysis of the Ang II-induced TGF-
b1 expression. Scanning densitometric values for TGF-b1 were
normalized with respective GAPDH mRNA values. Values are
means of the normalized signal 6 SEM (n 5 4) and expressed as
fold induction versus control (control value set at 1.0). #P < 0.05
versus control (control cells at 24 h).
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spective controls. Using a human-specific cDNA probe en-
coding TGF-b1, we detected an mRNA species of 2.4 kb in
human ASM cells (Figure 5A). TGF-b1 expression was
drastically increased (P < 0.001) in serum-fed cells as com-
pared with the control cells. Scanning laser densitometric
analysis of TGF-b1 expression showed that Ang II signifi-
cantly induced (P < 0.001) the steady-state mRNA levels
which became apparent after 8 h and reached a maximum
level at 16 h (P < 0.001) as compared with controls (Figure
5B). To evaluate whether the increase in mRNA levels for
TGF-b1 were accompanied with an increase in secreted
protein, biologically active TGF-b1 was measured in the
conditioned medium after stimulation of the ASM cells
with Ang II for various time intervals. Indeed, a significant
increase in TGF-b1 protein was observed after 8 h, which
remained elevated at 24 h (Table 1).
Discussion
This is the first study showing that Ang II, in the absence
of serum, induces hypertrophy in human airway smooth
muscle cells in vitro. In an attempt to discern whether
Ang II could induce cell hypertrophy, cell hyperplasia, or
both, we used several biochemical markers. On the basis
of [3H]leucine incorporation, protein over DNA accumu-
lation in the cell (33), MTT-reduction assays, and cell num-
ber determinations, our results clearly indicate a hyper-
trophic response to Ang II in human ASM cells. Our data
also show that Ang II induced an increase in [3H]thymi-
dine incorporation into DNA without significantly altering
the cell number in human ASM cells. Furthermore, the
magnitude of increase in [3H]thymidine incorporation was
much lower (55%) than that seen with FBS, suggesting that
Ang II may act as a weak mitogen for human ASM cells.
Studying vascular smooth muscle cells in vitro, several
groups have demonstrated cell proliferation (34) whereas
others have shown only cellular hypertrophy after Ang II
stimulation (15, 17, 35). Ang II-induced hypertrophy in
vascular smooth muscle cells has been shown to be associ-
ated with an increase in expression and secretion of the
autocrine growth factor platelet-derived growth factor-
AA (PDGF-AA) (15, 36). PDGF is a potent mitogen for
vascular smooth muscle cells and it is quite possible that in
analogy to these cells, human ASM cells express and se-
crete PDGF in response to Ang II, resulting in an increase
in DNA synthesis. Moreover, Ang II induces the synthesis
and release of other autocrine–paracrine mitogenic factors
such as endothelin-1 and basic fibroblastic growth factor
(8, 15). Therefore, in this study, Ang II-induced DNA syn-
thesis may be attributed to the autocrine induction of such
growth factors, although it does not appear that the cells
are capable of completing the cell cycle (i.e., no increase in
cell number). In this regard, Jahan and associates (37)
demonstrated that Ang II did not induce the transition of
aortic smooth muscle cells in the G0 phase to the G1 phase;
rather, it acted as a progression factor stimulating cells re-
maining in the G1 phase to synthesize protein and DNA.
Additionally, they found that PDGF stimulated the entry
of cells in the G0 phase into the G1 phase without a further
progression into the S and M phases, whereas Ang II incu-
bation stimulated the progression of these PDGF-pre-
treated G1 cells to the S and M phases. Perhaps, in our
study, DNA repair could also be partly responsible for the
increase in [3H]thymidine incorporation into DNA with
time in the Ang II-treated cells. 
In this study, we chose 60 h of serum-free culture condi-
tions in order to synchronize and growth-arrest human
ASM cells. Fluorescent-activated cell sorter analysis veri-
fied that more than 85% of cells were in the G0/G1 phase
of the cell cycle after 60 h of serum deprivation, allowing
us to examine the direct effects of Ang II on cell division
and growth. Others have reported earlier that 48 h of se-
rum deprivation was successful in growth-arresting ASM
cells in culture (10–12, 38). The data presented here dem-
onstrate that Ang II is a weak mitogen and a potent hyper-
trophic stimulus for human ASM cells in vitro. However,
the cellular mechanisms involved in Ang II-stimulated mi-
togenesis in ASM cells are undefined and may be distinct
from vascular smooth muscle cells.
Previous studies have established that Ang II can in-
duce a rapid increase of the growth-associated nuclear
proto-oncogenes c-myc, c-fos, c-jun, and egr-1 in a variety
of cell types (20, 22, 39). Similarly, in human ASM cells,
nuclear events associated with Ang II activation appear to
be the induction of immediate early genes (c-fos, c-jun,
and egr-1). The observed increase in DNA biosynthesis
could be attributed to the transient expression of the tran-
scription factors c-fos, c-jun, and egr-1, which have previ-
ously been reported to be involved in cell growth and dif-
ferentiation (18, 20, 21, 39). Additionally, the Fos and Jun
proteins form a heterodimeric complex known as the AP-1
transcription factor, which activates gene transcription by
binding to an AP-1 site in target genes that may subse-
quently contribute to cell proliferation and growth (19, 21,
40). Previous studies have demonstrated that Ang II stim-
ulates Ang II type-1 (AT1) receptor-mediated hypertrophy
in cardiac myocytes and hyperplasia in cardiac fibroblasts
(18, 41). In vascular smooth muscle cells, proliferative ef-
fects of Ang II are attributed to the AT1 receptor which is
coupled to G-proteins and classic intracellular second
messenger systems (42). In contrast, the function and the
signal transduction pathways for the AT2 receptor, which
exhibits only 32% homology to the AT1 receptor are not
fully understood. However, AT2 receptor-mediated growth
inhibition in endothelial cells treated with Ang II has been
reported (43). We might speculate that the Ang II-induced
upregulation of immediate early genes in human ASM
cells may be mediated via AT1 receptors. 
In the present study we have demonstrated that Ang II
induces TGF-b1 mRNA expression and the secretion of
TABLE 1
Effects of Ang II on secretion of biologically
active TGF-b1
Incubation Time with Ang II (h) Active TGF-b1 (pg/ml)
Control 161.6 6 12.0
8 446.0 6 3.0
24 393.3 6 11.9
Biologically active TGF-b1 was measured in the conditioned medium of hu-
man ASM cells treated with Ang II for 8 and 24 h as described in MATERIALS
AND METHODS. Values are means 6 SEM.
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biologically active TGF-b1 protein in human ASM cells.
Our findings are in agreement with previous reports where
Ang II has been shown to stimulate TGF- b1 both at
mRNA and protein levels in vascular smooth muscle cells
(17, 26, 34). One explanation for the induction of TGF-b1
seems to be the positive regulation by the AP-1 transcrip-
tion factor. The TGF-b1 promoter region contains an AP-1
site which can modulate TGF-b1 gene expression, suggest-
ing that the Ang II-induced expression of c-fos and c-jun
may participate in the induction of TGF-b1 gene expres-
sion (17, 44). Several groups have shown that the incuba-
tion of vascular smooth muscle cells with TGF-b1 induces
cellular hypertrophy and inhibits mitogen-stimulated pro-
liferation (34, 45, 46). Apart from the mechanisms involv-
ing induction of growth factors such as TGF- b1 and
PDGF, Ang II-induced hypertrophy in human ASM cells
may be attributed partly to changes in the contractile phe-
notype of these cells in response to Ang II stimulation.
Koibuchi and colleagues have shown that vascular smooth
muscle cell growth is mediated by the autocrine produc-
tion of active TGF-b1 (26). This may also be the case in
ASM cells. The autocrine production of biologically active
TGF-b1 is a major determinant of whether vascular smooth
muscle cells grow by hypertrophy or hyperplasia (17). It
remains to be determined whether the direct incubation of
human ASM cells with biologically active TGF-b1 can stim-
ulate cellular hypertrophy. 
In conclusion, we have established that Ang II induces
DNA biosynthesis and protein biosynthesis, with the net
effect being the accumulation of protein over DNA indi-
cating hypertrophy in human ASM cells. Caution must be
exercised in extrapolating from in vitro studies to in vivo
observations, but our data suggest a potentially important
role for Ang II in ASM growth in airway remodeling in
asthma. This possibility is supported by the findings that
plasma levels of Ang II are elevated in patients with acute
severe asthma (13, 14). Our results also demonstrate that
the ASM cells are activated by Ang II and that egr-1, c-fos,
and c-jun appear to be the primary response genes. The
transient expression of these transcription factors is evi-
dence in favor of induction of the nuclear transcriptional
machinery that can subsequently be involved in cellular
hypertrophy, since egr-1, c-fos, and c-jun upregulation gen-
erally precede the induction of growth-associated genes in
a wide variety of cells. Furthermore, the late and sustained
induction of TGF-b1 in response to Ang II could contrib-
ute, in an autocrine manner, to the process of hypertrophy
in human ASM cells. Hence, Ang II activates a prolifera-
tive pathway (increase in DNA synthesis), as well as a pos-
sible antiproliferative and hypertrophic pathway (TGF-b1
upregulation), such that the net effect is hypertrophy in
human ASM cells.
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